Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Operations: 2023-2025

Historic Cash from Operations for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to -$12.2 million.

  • Contineum Therapeutics' Cash from Operations fell 97.71% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.5 million, marking a year-over-year decrease of 57.35%. This contributed to the annual value of -$32.8 million for FY2024, which is 269.75% down from last year.
  • Per Contineum Therapeutics' latest filing, its Cash from Operations stood at -$12.2 million for Q3 2025, which was up 22.12% from -$15.7 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Cash from Operations registered a high of $40.7 million during Q2 2023, and its lowest value of -$15.7 million during Q2 2025.
  • Its 3-year average for Cash from Operations is -$5.1 million, with a median of -$8.5 million in 2024.
  • Over the last 5 years, Contineum Therapeutics' Cash from Operations had its largest YoY gain of 4.69% in 2024, and its largest YoY loss of 120.90% in 2024.
  • Contineum Therapeutics' Cash from Operations (Quarterly) stood at -$10.7 million in 2023, then climbed by 4.69% to -$10.2 million in 2024, then tumbled by 97.71% to -$12.2 million in 2025.
  • Its last three reported values are -$12.2 million in Q3 2025, -$15.7 million for Q2 2025, and -$14.4 million during Q1 2025.